Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIGHT: Capecitabine vs Endocrine Therapy in non-Luminal A HR+ Metastatic Breast Cancer
NCT05693766Phase 2Recruiting
- Sponsor
- Sonya Reid
- Start
- Sep 2023
- Primary completion
- Aug 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in breast cancer, sponsored by Sonya Reid. Started Sep 2023; status: recruiting.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05693766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05693766.